Physician profile
Surajit Saha
NPI 1629397526
$15,785.24
in general payments reported to CMS, 2019-2025
33 companies · $3,533 in 2025
The $3,533 reported for 2025 was more than what 92% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,392 · 2020: $303 · 2021: $1,597 · 2022: $1,939 · 2023: $3,871 · 2024: $3,150 · 2025: $3,533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,542 · Travel and Lodging: $995 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,541.50 |
| Travel and Lodging | $994.98 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $4,437.87 | 2022-2025 | Envista Mx60 Iol, Ic-8 Apthera Iol, Stellaris Elite |
| Mallinckrodt Hospital Products INC. | $2,251.69 | 2020-2025 | Acthar |
| Eyevance Pharmaceuticals LLC | $1,012.94 | 2020-2021 | |
| Biotissue Holdings INC. | $870.77 | 2019-2025 | |
| Alcon Vision LLC | $770.01 | 2019-2025 | Clareon, Tryptyr, Simbrinza |
| Sun Pharmaceutical Industries INC. | $709.75 | 2019-2025 | Cequa, Xelpros |
| Dompe US, INC. | $570.79 | 2019-2025 | Oxervate |
| Oyster Point Pharma, INC. | $518.21 | 2022-2025 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $458.57 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $455.96 | 2021-2025 | Idosetr, Istent Infinite, Idose |
| Johnson & Johnson Surgical Vision, INC. | $431.51 | 2019-2025 | Tecnis Simplicity, Tecnis Iol |
| Abbvie INC. | $423.71 | 2023-2025 | Ozurdex |
| Novartis Pharmaceuticals Corporation | $342.79 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $268.28 | 2024-2025 | Purified Cortrophin Gel |
| Astellas Pharma US INC | $254.71 | 2024-2025 | Izervay |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $247.74 | 2019-2021 | |
| Ocular Therapeutix, INC. | $237.00 | 2019-2025 | Dextenza |
| Harrow Eye, LLC | $232.97 | 2024-2025 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $223.74 | 2019-2021 | |
| Amgen INC. | $186.36 | 2024-2025 | Tepezza |
| Aerie Pharmaceuticals, INC. | $148.88 | 2019 | |
| New World Medical,INC. | $133.05 | 2019-2022 | |
| Horizon Therapeutics Plc | $132.91 | 2019-2023 | Tepezza |
| Mallinckrodt Enterprises LLC | $132.16 | 2019 | |
| Shire North American Group INC | $115.39 | 2019 | |
| Thea Pharma INC. | $69.76 | 2023-2024 | Iyuzeh |
| Eyepoint US, INC. | $48.90 | 2019-2020 | |
| Rayner Intraocular Lenses Limited | $27.47 | 2025 | Rayone Spheric, Rayner Cataract Set 1, Rayone Emv |
| Rxsight INC | $23.90 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Genentech USA, INC. | $16.24 | 2024 | Vabysmo |
| Notal Vision, INC. | $6.63 | 2019 | |
| Beaver-Visitec International, INC. | $5.18 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Surajit Saha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.